Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors

Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2

(2015) H. P. Soares et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of REV3 Expression Induces Persistent DNA Damage and Growth Arrest in Cancer Cells

(2015) Philip A. Knobel et al.   NEOPLASIA

GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells

(2014) Jian-ying Tang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Tumor Vessel Normalization by Chloroquine Independent of Autophagy

(2014) Hannelore Maes et al.   CANCER CELL

Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma

(2014) G. Guo et al.   CANCER RESEARCH

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

(2014) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy

(2014) Byron K.Y. Bitanihirwe et al.   Journal of Thoracic Oncology

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma

(2014) Rajani Kanteti et al.   PLoS One

XIAP Restricts TNF- and RIP3-Dependent Cell Death and Inflammasome Activation

(2014) Monica Yabal et al.   Cell Reports

Autophagy-Mediated Tumor Promotion

(2013) Jessie Yanxiang Guo et al.   CELL

Tsc1-Tp53 loss induces mesothelioma in mice and evidence for this mechanism in human mesothelioma

(2013) Y Guo et al.   ONCOGENE

Down-Regulation of Autophagy-Related Protein 5 (ATG5) Contributes to the Pathogenesis of Early-Stage Cutaneous Melanoma

(2013) H. Liu et al.   Science Translational Medicine

Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer

(2013) B Liu et al.   Cell Death & Disease

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

(2013) S. J. Klempner et al.   Cancer Discovery

Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin

(2012) Yandong Shi et al.   BMC CANCER

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosisviamitochondrial-lysosomal cross-talk

(2012) Christian Seitz et al.   INTERNATIONAL JOURNAL OF CANCER

Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)

(2012) S. Cedrés et al.   LUNG CANCER

Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy

(2012) Bruno Fischer et al.   LUNG CANCER

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma

(2012) Kyuichi Kadota et al.   MODERN PATHOLOGY

Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors

(2012) M. P. Ghadimi et al.   MOLECULAR CANCER THERAPEUTICS

Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation

(2012) P. B. Bitterman et al.   MOLECULAR CANCER THERAPEUTICS

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition

(2012) Kevin Bray et al.   PLoS One

Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy

(2011) Cheng-Xiong Xu et al.   CANCER BIOLOGY & THERAPY

Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma

(2011) Olga K. Mirzoeva et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

(2011) J. J. Wallin et al.   MOLECULAR CANCER THERAPEUTICS

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

(2011) Matthew Bott et al.   NATURE GENETICS

The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance

(2011) D Barbone et al.   Cell Death & Disease

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells

(2010) Caroline Brünner-Kubath et al.   BREAST CANCER RESEARCH AND TREATMENT

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

NVP-BEZ235 as a New Therapeutic Option for Sarcomas

(2010) M. C. Manara et al.   CLINICAL CANCER RESEARCH

Distinct 5′ UTRs regulate XIAP expression under normal growth conditions and during cellular stress

(2010) Alura Riley et al.   NUCLEIC ACIDS RESEARCH

Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma

(2010) Q.-W. Fan et al.   Science Signaling

Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates

(2009) J Daubriac et al.   CELL DEATH AND DIFFERENTIATION

Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling

(2009) M. A. Lopez-Lago et al.   MOLECULAR AND CELLULAR BIOLOGY

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Autophagy Inhibition Compromises Degradation of Ubiquitin-Proteasome Pathway Substrates

(2009) Viktor I. Korolchuk et al.   MOLECULAR CELL

Spheroid-based drug screen: considerations and practical approach

(2009) Juergen Friedrich et al.   Nature Protocols

Dynamics and diversity in autophagy mechanisms: lessons from yeast

(2009) Hitoshi Nakatogawa et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids

(2008) Dario Barbone et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Functional inactivation of NF2/merlin in human mesothelioma

(2008) Claudio Thurneysen et al.   LUNG CANCER

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Identification of RIP1 kinase as a specific cellular target of necrostatins

(2008) Alexei Degterev et al.   Nature Chemical Biology